Finally, the researchers showed that a treatment with an anti-VEGFR-2 antibody had a preventive and therapeutic role in decreasing steatosis and inflammation in the liver of mice with NASH. The gene discussed is KDR; the disease is metabolic dysfunction-associated steatohepatitis.